Pernix Therapeutics Holdings (AMEX: PTX) reported earnings on Aug. 14. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended June 30 (Q2), Pernix Therapeutics Holdings missed estimates on revenues and missed expectations on earnings per share.

Compared to the prior-year quarter, revenue dropped and GAAP earnings per share shrank to a loss.

Margins contracted across the board.

Revenue details
 Pernix Therapeutics Holdings chalked up revenue of $10.5 million. The five analysts polled by S&P Capital IQ anticipated a top line of $10.7 million on the same basis. GAAP reported sales were 13% lower than the prior-year quarter's $12.0 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at -$0.03. The five earnings estimates compiled by S&P Capital IQ anticipated $0.00 per share. GAAP EPS were -$0.03 for Q2 compared to $0.07 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 67.5%, 870 basis points worse than the prior-year quarter. Operating margin was -13.8%, 4,250 basis points worse than the prior-year quarter. Net margin was -8.9%, 2,140 basis points worse than the prior-year quarter.

Looking ahead
 Next quarter's average estimate for revenue is $16.9 million. On the bottom line, the average EPS estimate is $0.04.

Next year's average estimate for revenue is $71.1 million. The average EPS estimate is $0.25.

Investor sentiment

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Pernix Therapeutics Holdings is buy, with an average price target of $14.40.